- Conditions
- Advanced Solid Tumors
- Interventions
- INCB081776, INCMGA00012
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Hackensack, New Jersey + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 37
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Endometrial Cancer
- Interventions
- retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 26 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
- Interventions
- Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Glioblastoma Multiforme
- Interventions
- Retifanlimab, Temozolomide, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
- Interventions
- INCB106385, INCMGA00012
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
- Conditions
- Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Interventions
- Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Newark, Delaware • Jacksonville, Florida + 17 more
- Conditions
- Glioblastoma
- Interventions
- INCMGA00012, INCAGN01876, SRS, Brain surgery
- Drug · Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
- Interventions
- Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Retifanlimab
- Biological · Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Metastatic Merkel Cell Carcinoma
- Interventions
- Retifanlimab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 13 more
- Conditions
- Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
- Interventions
- INCMGA00012 (PD-1 antibody)
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Glioma, Glioblastoma
- Interventions
- Epacadostat, Bevacizumab, Radiation therapy, Retifanlimab
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
- Interventions
- Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab, Tumor Resection
- Procedure · Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Squamous Cell Carcinoma of the Anal Canal
- Interventions
- carboplatin, paclitaxel, retifanlimab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Duarte, California • Sacramento, California + 11 more
- Conditions
- Cancer of the Head and Neck
- Interventions
- INCAGN01876, INCMGA00012, DPV-001
- Drug · Biological
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Interventions
- margetuximab, Retifanlimab, Tebotelimab, Trastuzumab, Chemotherapy
- Biological · Other
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 28
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 25 more
- Conditions
- Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
- Interventions
- SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation, retifanlimab
- Biological · Drug
- Lead sponsor
- BriaCell Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 14
- States / cities
- Newport Beach, California • Santa Rosa, California • Jacksonville, Florida + 11 more
- Conditions
- Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
- Interventions
- Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Retifanlimab
- Biological · Procedure · Other + 1 more
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- 9-ING-41, Retifanlimab, Gemcitabine, Abraxane
- Drug
- Lead sponsor
- Anwaar Saeed
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Fairway, Kansas • Pittsburgh, Pennsylvania
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN
- Interventions
- Pemigatinib, Gemcitabine, Pembrolizumab, Docetaxel, Trastuzumab, Retifanlimab, Cisplatin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 16 more
- Conditions
- Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
- Interventions
- Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, Quality-of-Life Assessment, Short-Term Fasting, Dostarlimab, Retifanlimab, Toripalimab, Tislelizumab
- Drug · Biological · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Well-differentiated/Dedifferentiated Liposarcoma
- Interventions
- INCMGA00012, Palbociclib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Advanced Malignancies
- Interventions
- Pemigatinib, Retifanlimab, Pembrolizumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Charlotte, North Carolina • Houston, Texas + 2 more
- Conditions
- Melanoma
- Interventions
- INCAGN02385, INCAGN02390, INCMGA00012.
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Miami, Florida • Tampa, Florida + 9 more
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- MGD007 + MGA012
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 3 more